Drug Combinations of Atovaquone-Proguanil (AP) With ACT
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Investigators are conducting this study due to recent reports of many of existing malaria
drugs becoming less effective for treatment of malaria. The drugs may not always kill all the
parasites, therefore not all patients with malaria are being cured. The main objective of the
study is to find out which malaria drugs and what drug combinations are still effective in
Cambodia, an area of multi-drug resistance where 4-5 artemisinin-based combination therapies
have shown inadequate response, below that established by the World Health Organization
(WHO). New drug combinations (taking more than one drug for malaria at the same time), as
long as well tolerated, can provide cure in patients that harbor parasites not responsive to
standard first-line medications. Human genetic testing will be done to identify patients who
may have suboptimal response to treatments and to study the differences in human gene
expression to explain why some persons are at higher risk of complications during treatment.
Markers of drug resistance to commonly used antimalarial drugs will also be evaluated and
shared with national malaria program (CNM) to better guide future malaria treatment decisions
in Cambodia.
Phase:
Phase 4
Details
Lead Sponsor:
Armed Forces Research Institute of Medical Sciences, Thailand
Collaborators:
National Center for Parasitology, Entomology and Malaria Control National Center for Parasitology, Entomology, and Malaria Control (CNM) Naval Medical Research Unit-2 (NAMRU-2)
Treatments:
Artemisinins Artesunate Atovaquone Atovaquone, proguanil drug combination Mefloquine Proguanil Pyronaridine